{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Neill E"],"funding":["National Health and Medical Research Council"],"pagination":["1263-1272"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9673271"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["48(6)"],"pubmed_abstract":["Background and hypothesis
Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, yet a significant proportion of individuals on clozapine continue to experience disabling symptoms, despite being treated with an adequate dose. There is a need for adjunct treatments to augment clozapine, notably for negative and cognitive symptoms. One such potential agent is the glutathione precursor N-acetylcysteine (NAC).Study design
A randomized double-blind, multi-center, placebo-controlled trial for clozapine patients with enduring psychotic symptoms (n = 84) was undertaken to investigate the efficacy of adjunctive NAC (2 g daily) for negative symptoms, cognition and quality of life (QoL). Efficacy was assessed at 8, 24, and 52 weeks.Study results
NAC did not significantly improve negative symptoms (P = .62), overall cognition (P = .71) or quality of life (Manchester quality of life: P = .11; Assessment of quality of life: P = .57) at any time point over a 1-year period of treatment. There were no differences in reported side effects between the groups (P = .26).Conclusions
NAC did not significantly improve schizophrenia symptoms, cognition, or quality of life in treatment-resistant patients taking clozapine. This trial was registered with \"Australian and New Zealand Clinical Trials\" on the 30 May, 2016 (Registration Number: ACTRN12615001273572)."],"journal":["Schizophrenia bulletin"],"pubmed_title":["N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms."],"pmcid":["PMC9673271"],"funding_grant_id":["NHMRC GNT1098442"],"pubmed_authors":["Galletly C","Meyer D","Yolland C","Dark F","Berk M","Neill E","Bozaoglu K","Rossell SL","Castle DJ","Harris A","Francis PS","Phillipou A","Dean OM","Siskind D","Liu D","Sarris J"],"additional_accession":[]},"is_claimable":false,"name":"N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms.","description":"Background and hypothesis
Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, yet a significant proportion of individuals on clozapine continue to experience disabling symptoms, despite being treated with an adequate dose. There is a need for adjunct treatments to augment clozapine, notably for negative and cognitive symptoms. One such potential agent is the glutathione precursor N-acetylcysteine (NAC).Study design
A randomized double-blind, multi-center, placebo-controlled trial for clozapine patients with enduring psychotic symptoms (n = 84) was undertaken to investigate the efficacy of adjunctive NAC (2 g daily) for negative symptoms, cognition and quality of life (QoL). Efficacy was assessed at 8, 24, and 52 weeks.Study results
NAC did not significantly improve negative symptoms (P = .62), overall cognition (P = .71) or quality of life (Manchester quality of life: P = .11; Assessment of quality of life: P = .57) at any time point over a 1-year period of treatment. There were no differences in reported side effects between the groups (P = .26).Conclusions
NAC did not significantly improve schizophrenia symptoms, cognition, or quality of life in treatment-resistant patients taking clozapine. This trial was registered with \"Australian and New Zealand Clinical Trials\" on the 30 May, 2016 (Registration Number: ACTRN12615001273572).","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-05T10:57:42.329Z","creation":"2025-04-05T10:57:42.329Z"},"accession":"S-EPMC9673271","cross_references":{"pubmed":["35857752"],"doi":["10.1093/schbul/sbac065"]}}